Journal for ImmunoTherapy of Cancer posted on X about recent paper by Brian S. Henick et al., titled “Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings“.
Authors: Brian S. Henick, Peter D. Koch, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Stephanie Izard, Yohanna Georgis, Samyukta Mallick, Robert F. Garofano, Cheryl V. Wong, Anjali Saqi, Jessica Grindheim, Katja Schulze, Joshua R. Sonett, Naiyer A. Rizvi, Benjamin Izar, Alison M. Taylor, Catherine A. Shu
“New JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.”